Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol provided greater increases in lung function compared to once-daily fluticasone furoate/vilanterol in patients with poorly controlled asthma.
FEV1 increased in patients with aspirin-tolerant asthma while on standard asthma treatment but declined in patients with aspirin-exacerbated respiratory disease.
Children with asthma and atopic dermatitis experience worse sleep and lung function outcomes compared with children with asthma alone.
Treatment with 300 mg lanadelumab every 2 weeks significantly reduced monthly hereditary angioedema attack rates compared with the 3-month historic baseline.
Although women are more likely than men to experience more severe asthma, they respond similarly to benralizumab therapy.
Prenatal exposure to calcium carbonate antacids was associated with the development of food protein-induced allergic proctocolitis, a type of delayed inflammatory gut food allergy to protein, in offspring.
In patients with chronic rhinosinusitis with nasal polyps, regardless of their asthma status, omalizumab was associated with improvements in nasal polyps score, nasal congestion score, and sinonasal outcome test score.
Repeated cycles of treatment with crisaborole may be necessary to achieve and maintain control of atopic dermatitis symptoms.
Drug reaction with eosinophilia and systemic symptoms (DReSS) with exposure to interleukin-1 or interleukin-6 inhibition may be linked to high fatality lung disease in systemic juvenile idiopathic arthritis.
Epinephrine is more often prescribed for venom allergy and idiopathic anaphylaxis than for food allergy despite its potential as a life-saving drug for allergic reactions.
Want to read more?
Please login or register first to view this content.